Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BCL2A1 neoepitope-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer.

Journal of leukocyte biology - 2 Sept 2024

Lin Shengzhe, Hong Jingwen, Wu Suxin, Zhu Chenlu, Liu Fang, Lin Wansong, Cai Xinran, Ye Yunbin, Chen Yanling

Abstract excerpt

Conventional treatments have shown a limited efficacy for pancreatic cancer, and immunotherapy is an emerging option for treatment of this highly fatal malignancy. Neoantigen is critical to improving the efficacy of tumor-specific immunotherapy. The cancer and peripheral blood specimens from an HLA-A0201-positive pancreatic cancer patient were subjected to next-generation sequencing, and bioinformatics analyses...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to Dendritic Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epitopes

Share to HLA-A2 Antigen

Share to Immunotherapy

Share to Minor Histocompatibility Antigens

Share to Proto-Oncogene Proteins c-bcl-2

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 38626292
DOI: 10.1093/jleuko/qiae092

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BCL2A1 neoepitope-elicited cytotoxic T lymphocytes are a promising individualized immunotherapy of pancreatic cancer.PMID 38626292Read ↗

A Peptide-Based Neoantigen Vaccine for Patients With Advanced Pancreatic Cancer Refractory to Standard TreatmentSemantic proximity Read ↗

Cancer neoantigens as potential targets for immunotherapy.Semantic proximity Read ↗

Neoantigens in Cancer Immunotherapy: An Overview with a Focus on Non-small Cell Lung Cancer and Pancreatic Ductal Adenocarcinoma.Semantic proximity Read ↗

Identification and characterization of neoantigen-reactive CD8+ T cells following checkpoint blockade therapy in a pan-cancer settingSemantic proximity Read ↗

Engineering neoantigen vaccines to improve cancer personalized immunotherapySemantic proximity Read ↗

MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapySemantic proximity Read ↗

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read ↗

Stimulating T cell responses against patient-derived breast cancer cells with neoantigen peptide-loaded peripheral blood mononuclear cellsSemantic proximity Read ↗

Enhancing cholangiocarcinoma immunotherapy with adoptive T cells targeting HLA-restricted neoantigen peptides derived from driver gene mutations.Semantic proximity Read ↗

Identification of neoantigens in esophageal adenocarcinomaSemantic proximity Read ↗

[A method of screening highly common neoantigens with immunogenicity in colorectal cancer based on public somatic mutation library].Semantic proximity Read ↗

PCI-DB: A novel primary tissue immunopeptidome database to guide next-generation peptide-based immunotherapy developmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.